Articles tagged "Kidney transplantation"

2019 American Transplant Congress
Donor-Derived Cell-Free DNA is Associated Specifically with Antibody Mediated Injury in Patients with Renal Allograft Dysfunction
B. Obrisca¹, C. Blosser², I. De Castro², C. Johnson², B. Sorohan¹, L. Sibulesky², R. Bakthavatsalam², G. Ismail¹, N. Leca²
¹Fundeni Clinical Institute, Bucharest, Romania, ²University of Washington, Seattle, WA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) has been proposed as a noninvasive biomarker to differentiate rejection from other types of injury in renal allografts.*Methods: We analyzed…
2019 American Transplant Congress
Management of Inactive Candidates on the Kidney Transplant Waitlist: Results from a National Survey
J. Hiller, J. Chen, K. Covarrubias, K. Jackson, J. Long, S. DiBrito, D. Segev, J. Garonzik Wang
Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: As the inactive deceased donor kidney transplant (DDKT) waitlist pool continues to grow, management of these patients has become an increasingly complex administrative undertaking.…
2019 American Transplant Congress
Dosing and Exposure over 2 Years with LCP-Tacrolimus (LCPT) vs. Immediate-Release Tacrolimus (IR-Tac) in De Novo Kidney Transplantation
K. Budde¹, S. Bunnapradist², S. Patel³, D. Stevens³, U. Meier-Kriesche³, B. Suwelack⁴
¹Charité University Medicine Berlin, Berlin, Germany, ²UCLA Medical Center, Los Angeles, CA, ³Veloxis Pharmaceuticals Inc, Cary, NC, ⁴University Hospital of Münster, Münster, Germany
*Purpose: A prospective study demonstrated safe and efficacious use of LCPT in de novo kidney transplantation. This study aims to evaluate tacrolimus trough levels and…
2019 American Transplant Congress
Assessment of Proteinuria Reported as Adverse Events in De Novo Renal Transplant Recipients Receiving an Everolimus-Based Regimen: 24-Month Results from TRANSFORM
C. Legendre¹, S. Berger¹, F. Oppenheimer¹, A. Wiseman¹, S. Steinberg¹, O. Viklicky¹, G. Russ¹, R. Danguilan¹, N. Basic-Jukic¹, E. Mor¹, P. Narvekar², M. P. Hernandez Gutierrez², P. Bernhardt², C. Sommerer¹
¹TRANSFORM Study Group, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland
*Purpose: mTOR inhibitors (eg, everolimus [EVR]), are thought to increase the risk of post-transplant (Tx) proteinuria (PU). Here, we assess PU onset and outcomes in…
2019 American Transplant Congress
Long-Term Outcomes of Early Conversion to Sirolimus-Based Immunosuppression in Children with Living Donor Kidney Transplants
B. Stotter¹, S. Lui¹, E. Weller², L. Ganapathi¹, M. Ferguson¹, A. Traum¹, M. Somers¹, N. Rodig¹
¹Pediatrics, Boston Children's Hospital, Boston, MA, ²Biostatistics and Research Design Center, Boston Children's Hospital, Boston, MA
*Purpose: Following kidney transplantation (KTx), calcineurin inhibitor (CNI)-based maintenance immunosuppression (IS) can be associated with nephrotoxicity and other complications including viral infections and malignancy. Mammalian…
2019 American Transplant Congress
The Molecular Profile of Kidney Allografts Unveil Specific Biomarkers for Subclinical Acute Rejection (SAR). Towards an Early Detection and a Targeted Treatment
S. N. Cox, S. Chiurlia, F. P. Schena
Schena Foundation, Valenzano-Bari, Italy
*Purpose: SAR diagnosed by protocol biopsy is an independent risk factor for chronic allograft injury. We organized a molecular study on 24 AB0 compatible cadaveric…
2019 American Transplant Congress
Multi-Center Validation of TruGraf V2 – A Peripheral Blood Diagnostic for Subclincal Kidney Rejection
C. Marsh¹, S. Kurian¹, C. Schieve², R. Heilman³, M. Stegall⁴, S. Rose², J. Case¹, J. Friedewald⁵, M. Abecassis⁵, R. First²
¹Scripps Health, La Jolla, CA, ²Transplant Genomics Inc., Mansfield, MA, ³Mayo Clinic, Scottsdale, AZ, ⁴Mayo Clinic, Rochester, MN, ⁵Northwestern University, Chicago, IL
*Purpose: Unsuspected subclinical acute rejection (subAR) is currently only detectable in 15-25% of invasive surveillance biopsies (SB) and can lead to chronic rejection and poor…
2019 American Transplant Congress
Differential Effects Of Prolonged Cold Ischemia On Outcomes In Donation After Cardio Circulatory Death Versus Acute Kidney Injury Donor Kidney Transplants
D. Harriman, V. Gurram, J. Rogers, A. Farney, G. Orlando, C. Jay, A. Reeves-Daniel, A. Mena-Gutierrez, M. Gautreaux, W. Doares, S. Kaczmorski, R. Stratta
Wake Forest Baptist Medical Center, Winston-Salem, NC
*Purpose: Donation after cardio-circulatory death (DCD) and acute kidney injury (AKI) deceased donor (DD) kidneys increase the organ pool but their rates of discard and…
2019 American Transplant Congress
Sequential Dosing of Rituximab and IVIg for Desensitization of Highly-HLA Sensitized (HS) Patients Awaiting HLAi Kidney Transplantation
A. A. Vo, E. Huang, S. Williamsons, C. Myers, A. Peng, R. Najjar, S. Sethi, K. Lim, N. Ammerman, S. C. Jordan
Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Recent observations suggest that the use of IVIg + rituximab has a critical role in modifying allo-reactive B-cells prior to HLAi kidney transplantation, thus…
2019 American Transplant Congress
Impact of Protease Inhibitor-Based Anti-Retroviral Therapy on Tacrolimus Intrapatient Variability in HIV+ Kidney Transplant Recipients
M. H. Cooper, I. E. Dunne, S. A. Kuten, A. E. Cantwell, E. A. Graviss, D. T. Nguyen, M. J. Hobeika, A. O. Gaber
Houston Methodist Hospital, Houston, TX
*Purpose: High tacrolimus (FK) intra-patient variability (IPV) has been associated with inferior outcomes in solid organ transplantation. HIV+ transplant recipients have been shown to experience…